|
Glioma Treatment Utilizing Ep2 Antagonists (118014)
With 17,000 new cases diagnosed each year in the United States, malignant gliomas account for about 80% of all primary malignant brain tumors, with 82% of these cases classified as a grade IV tumor—glioblastoma multiforme (GBM). The median survival time of GBM patients from diagnosis with treatment is only about 15 months. Malignant gliomas are...
Published: 8/30/2023
|
Updated: 8/30/2023
|
Inventor(s): Jianxiong Jiang
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Diseases & Disorders > Cancer, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Diseases & Disorders > Neurologic, Technology Classifications > Life Sciences > Therapeutics > Small Molecule, Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Diseases & Disorders
|
|
Method for Treating Acute Myeloid Leukemia with a Mir-22 Nanoparticle (117-006)
Acute Myeloid Leukemia (AML) is one of the most common and fatal forms of hematopoietic malignancies. Despite intensive chemotherapies, the majority of patients with AML fail to survive longer than 5 years. MicroRNA-22 (miR-22) has recently been shown to be an essential anti-tumor gatekeeper in various types of AML. Nanoparticles complexed with either...
Published: 8/30/2023
|
Updated: 8/30/2023
|
Inventor(s): Xi Jiang, Jianjun Chen
Keywords(s):
Category(s): Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Biomedical
|
|
Methods for Treating Acute Myeloid Leukemia with Mir-150 Nanoparticles (116-038)
Acute myeloid leukemia (AML) is one of the most common and fatal forms of hematopoietic malignancies. With standard chemotherapies, only 30-40% AML patients under 60 and 5-15% of AML patients older than 60 survive more than 5 years. One avenue for new treatment is through treatment with microRNAs (miRNA); however, successful clinical implementation...
Published: 8/30/2023
|
Updated: 8/30/2023
|
Inventor(s): Zejuan Li, Seungpyo Hong, Xi Jiang, Jianjun Chen
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Diseases & Disorders > Cancer, Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Diseases & Disorders, Technology Classifications > Life Sciences > Biomedical, Technology Classifications > Life Sciences > Therapeutics
|